- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03279094
Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease
A Pilot Study of Pre-transplant Immunosuppressive Therapy for Haploidentical Transplants in Patients With Sickle Cell Disease
This is a study to evaluate the safety and toxicity of a treatment regimen consisting of 2 cycles of pre-transplant immunosuppressive therapy followed by myeloablative preparative regimen and allogeneic hematopoietic stem cell transplantation from a haploidentical donor in patients with sickle cell disease.
The overall goal of this study is to expand the donor pool for hematopoietic stem cell transplantation in sickle cell disease using haploidentical donors, and to develop a non-toxic, myeloablative regimen, with the goal of achieving a consistent donor chimerism utilizing pre-transplant immunosuppressive therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All patients will receive an haploidentical hematopoietic stem cell transplant with the following conditioning and GvHD prevention:
Pre-transplant immunosuppressive therapy:
2 cycles of Fludarabine and Dexamethasone x 5 days each cycle
Conditioning regimen:
rATG daily x 3 days, Fludarabine daily x 6 days and Busulfan daily x 4 days
GVHD prophylaxis:
Cyclophosphamide day +3 and +4, Tacrolimus and Mycophenolate mofetil
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Anna B. Pawlowska, MD
- Phone Number: 626-218-8442
- Email: apawlowska@coh.org
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Medical Center
-
Contact:
- Mary Suarez, CRC
- Phone Number: 626-218-5795
- Email: masuarez@coh.org
-
Principal Investigator:
- Anna B. Pawlowska, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- Diagnosis: Patients with sickle cell anemia (Hgb SS or SB° Thalassemia) with baseline Hgb S more than 60%.
- Disease status:
- Significant neurologic event (stroke) or any neurological deficit lasting > 24 hours; or increased transcranial Doppler velocity (>200 m/s).
- History of one or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea).
- History of one or more severe vaso-occlusive pain crises per year in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea).
- Recurrent priapism requiring medical therapy.
- Osteonecrosis of two or more joints despite the institution of supportive care measures.
- Prior treatment with regular RBC transfusion therapy, defined as receiving 8 or more transfusions per year for > 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)
- Echocardiograph finding of tricuspid valve regurgitation jet (TRJ) velocity ≥ 2.5 m/sec.
- Ages 1 to 30.
- Child Bearing Potential- Transplantation could be teratogenic and/or lethal to the developing fetus. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately.
- Informed Consent/Assent: All subjects must have the ability to understand and the willingness to sign a written informed consent.
- The recipient must have a related donor who is genotypically haploidentical on HLA-A, B, C and DRB1 loci.
- No HLA matched sibling or 10/10 matched unrelated donor is available.
Exclusion criteria:
- Any uncontrolled illness including ongoing or active bacterial, viral or fungal infection.
- Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the pre- or post-transplant regimen.
- Pregnant women are excluded from this study.
- Patients with any active malignancy are ineligible for this study, other than non-melanoma skin cancers.
- Medical problem or neurologic/psychiatric dysfunction which would impair patient ability to be compliant with the medical regimen and to tolerate transplantation or would prolong hematologic recovery which in the opinion of the principal investigator would place the recipient at unacceptable risk.
- Prior autologous or allogeneic transplant.
- Fully HLA-matched related or unrelated donor is available to donate.
- Non-Compliance: Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Haploidentical stem cell transplantation
|
Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of unacceptable adverse events that are defined as any of the following events that occur from start of pre-transplant immunosuppressive therapy to the first 100 days post HCT:
Time Frame: 190 days
|
|
190 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to donor neutrophil engraftment
Time Frame: 24 months
|
Day of Neutrophil Engraftment: The first of three consecutive days on which the ANC is ≥0.5x109/L
|
24 months
|
Time to donor platelets engraftment
Time Frame: 24 months
|
Day of Platelet engraftment: The first documented day on which the platelet count is >20x109/L unsupported by platelet transfusions for 7 days
|
24 months
|
Rate of graft failure
Time Frame: 24 months
|
Primary graft failure is defined as failure to achieve a neutrophil count of 0.5 x 109/L before day +42 or mixed chimerism with failure to achieve <30% Hgb S on electrophoresis after day +180.
Secondary graft failure is defined as recovery followed by a sustained loss of initial graft.
|
24 months
|
Incidence of acute GvHD (grade II - IV) during the first 100 days after transplantation
Time Frame: 100 days after transplantation
|
100 days after transplantation
|
|
Incidence of chronic GvHD
Time Frame: 24 months
|
24 months
|
|
Overall survival rate
Time Frame: 24 months
|
• Overall survival: the time from start of PTIS to death, or last follow-up, whichever comes first.
|
24 months
|
Event-free survival rate
Time Frame: 24 months
|
• Event-free survival: the time from start of PTIS to death, the unacceptable events, or last follow-up, whichever comes first.
|
24 months
|
Disease free survival rate
Time Frame: 24 months
|
• Disease free survival: the time from HCT to death, secondary graft failure, or last follow-up, whichever comes first.
|
24 months
|
Immune reconstitution at day 100, 180 and 365
Time Frame: 24 months
|
• Immune reconstitution: measurement of CD3, CD4, CD8, CD11b, CD14, CD56, CD20/19, FoxP3+ Treg, and memory subsets.
|
24 months
|
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 from start of pre-transplant immunosuppressive therapy to 24 months post transplant
Time Frame: 24 months post-transplant
|
24 months post-transplant
|
|
Percent of donor chimerism at 12 and 24 months after HCT
Time Frame: 12 and 24 months after HCT
|
12 and 24 months after HCT
|
|
Change From Baseline in Pain Scores using Numerical Rating Scale or Faces Pain Rating Scale at 100 days, 6 months and 12 months post-transplant
Time Frame: 100 days, 6 months and 12 months post-transplant
|
100 days, 6 months and 12 months post-transplant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anna B. Pawlowska, MD, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17136
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Hematopoietic stem cell transplantation
-
University of ZurichRecruitingEnd Stage Renal DiseaseSwitzerland
-
Wake Forest University Health SciencesCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Roswell Park Cancer InstituteCelgeneWithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Blasts Under 5 Percent of Peripheral Blood White Cells | Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment LevelUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
IRCCS Burlo GarofoloCompletedHematopoietic Stem Cell Transplantation
-
Peking UniversityUnknown
-
Richard Burt, MDTerminatedRetinal DiseaseUnited States
-
Azienda Ospedaliera San Giovanni BattistaUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedAcute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Minimal Residual Disease | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic... and other conditionsUnited States
-
Northwestern UniversityTerminated